GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Brain+ AS (OCSE:BRAINP) » Definitions » Additional Paid-In Capital

Brain+ AS (OCSE:BRAINP) Additional Paid-In Capital : kr0.00 Mil(As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Brain+ AS Additional Paid-In Capital?



Brain+ AS Additional Paid-In Capital Historical Data

The historical data trend for Brain+ AS's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brain+ AS Additional Paid-In Capital Chart

Brain+ AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
- - - - -

Brain+ AS Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only - - - - -

Brain+ AS Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Brain+ AS Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Brain+ AS's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Brain+ AS Business Description

Traded in Other Exchanges
N/A
Address
Kobmagergade 53, 3rd Floor, Copenhagen, DNK, 1150
Brain+ AS is a digital therapeutics company. It restores patients' quality of life by treating and detecting a cognitive decline in Alzheimer's disease and dementia through digital means. It has developed a set of Digital Medicine technologies. Its product pipeline includes CST Therapist Companion, and CST Home Companion; CST Home Care; CST for Mild Cognitive Impairment (MCI).

Brain+ AS Headlines

No Headlines